

# Guard Therapeutics changes Certified Adviser to Redeye AB

**Guard Therapeutics (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will assume the role of Certified Adviser on 8 December 2025.**

**For further information, please contact:**

---

**Tobias Agervald, CEO**

Telephone: +46 8 670 65 51

E-mail: [info@guardtherapeutics.com](mailto:info@guardtherapeutics.com)

**About Guard Therapeutics**

---

Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with a large unmet medical need, focusing on different forms of kidney disease. The company's candidate drugs are based on the endogenous protein alpha-1-microglobulin. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm (ticker: GUARD).

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, [www.skmg.se](http://www.skmg.se).

**Attachments**

---

[Guard Therapeutics changes Certified Adviser to Redeye AB](#)